T-Cell Lymphoma: Causes, Symptoms, Treatment and Prognosis — Overview, Diagnosis & Treatment Options | MyMedicPlus

Name: T-Cell Lymphoma: Causes, Symptoms, Treatment and Prognosis
Published: 2026-06-26

Updated: 2026-06-26

Quick Facts

Cancer Type

T-Cell Non-Hodgkin Lymphoma (Multiple Subtypes)

Key Biomarker

ALK, CD30, EBV (EBER), HTLV-1, TET2/RHOA (AITL)

Treatment

BV-CHP (ALCL), CHOP/CHOEP (PTCL), L-Asp Regimens (ENKTL), Auto-SCT

5- Year Survival

70-80% (ALK+ ALCL); 30-40% (PTCL-NOS/AITL); <20% (disseminated ENKTL)

Last Reviewed

2026-06-15

Reviewer

MyMedicPlus Medical Review Board

Overview: T-Cell Lymphoma

T-cell lymphomas (TCL) are a heterogeneous group of non-Hodgkin lymphomas arising from T-lymphocytes, comprising approximately 10-15% of all NHLs. Major subtypes: peripheral T-cell lymphoma NOS (PTCL-NOS, ~25%), angioimmunoblastic T-cell lymphoma (AITL, ~20%), anaplastic large cell lymphoma (ALCL: ALK-positive and ALK-negative), adult T-cell leukemia/lymphoma (ATLL), and extranodal NK/T-cell lymphoma (ENKTL).

Causes & Risk Factors

HTLV-1 retroviral infection (endemic in Japan, Caribbean, and Central Africa) causes adult T-cell leukemia/lymphoma. EBV is associated with AITL and extranodal NK/T-cell lymphoma. Immunosuppression (HIV, post-transplant) increases risk. Key genetic alterations: TET2 and RHOA mutations (AITL), ALK gene fusions with t(2;5)(p23;q35) translocation in ALK-positive ALCL.

Symptoms & Signs

Peripheral or generalized lymphadenopathy, B symptoms (fever, drenching night sweats, weight loss >10%), hepatosplenomegaly, skin involvement (CTCL: mycosis fungoides, Sézary syndrome). ALCL: often presents with systemic disease and bone marrow involvement. ENKTL: nasal obstruction, epistaxis, midline facial destruction. ATLL: leukemic cells, hypercalcemia, skin lesions.

Diagnosis & Staging

Lymph node or tissue biopsy with immunohistochemistry (CD2, CD3, CD4, CD5, CD7, CD8, CD30, ALK) and T-cell receptor gene rearrangement studies. PET/CT for staging. Bone marrow biopsy. ALK testing (IHC and FISH) for ALCL. HTLV-1 and EBV serology. Comprehensive NGS increasingly used for subtype-specific mutations (RHOA G17V, TET2, IDH2 in AITL). ENKTL: EBV in situ hybridization (EBER).

Treatment Options

ALK-positive ALCL: brentuximab vedotin plus CHP (BV-CHP, replacing CHOP) is the FDA-approved first-line regimen with superior outcomes. PTCL-NOS, AITL: CHOP or CHOEP; consolidation with autologous SCT for eligible patients in first remission. ENKTL: L-asparaginase-based regimens (SMILE, AspaMetDex). ATLL: aggressive subtypes: allogeneic SCT; mogamulizumab for relapsed/refractory. Pralatrexate, romidepsin, belinostat for relapsed PTCL.

Prognosis & Outlook

ALK-positive ALCL: best prognosis among T-cell lymphomas, with 5-year OS approximately 70-80% with BV-CHP. ALK-negative ALCL: approximately 50% 5-year OS. PTCL-NOS: 5-year OS approximately 30-40%. AITL: approximately 30-40%. ENKTL disseminated: approximately 20-30%. ATLL acute/lymphomatous subtypes: median OS less than 12 months with conventional therapy.

Frequently Asked Questions

ALK-positive anaplastic large cell lymphoma (ALCL) contains a t(2;5) translocation producing the NPM-ALK fusion protein, a constitutively active kinase. This molecular marker defines a younger patient group with high response rates to chemotherapy and now to brentuximab vedotin (BV-CHP). 5-year OS is approximately 70-80%, far better than other PTCL subtypes.

Brentuximab vedotin (BV) is an antibody-drug conjugate targeting CD30, which is expressed on ALCL cells. It delivers the cytotoxic agent monomethyl auristatin E (MMAE) directly to CD30-positive cells. BV plus CHP replaced CHOP as the standard first-line treatment for CD30-positive PTCL (ALCL and other CD30-high subtypes) based on the ECHELON-2 trial.

ENKTL is EBV-driven and historically treated with anthracycline-based regimens with poor results. L-asparaginase-based regimens (SMILE: dexamethasone-methotrexate-ifosfamide-L-asparaginase-etoposide; AspaMetDex) have significantly improved outcomes. Early-stage nasal ENKTL: concurrent IMRT plus chemotherapy. Pembrolizumab shows activity in relapsed disease (high PD-L1 expression).

Yes. Autologous SCT in first complete remission is recommended for eligible patients with PTCL-NOS, AITL, and ALK-negative ALCL who achieve remission with first-line chemotherapy. It consolidates remission and improves PFS, though its impact on OS remains debated. Allogeneic SCT is reserved for relapsed/refractory disease or ATLL.

References

National Cancer Institute (NCI). cancer.gov
American Cancer Society. cancer.org
UpToDate clinical decision support. uptodate.com
NCCN Clinical Practice Guidelines in Oncology. nccn.org

Medically Reviewed

Our medical content follows strict editorial guidelines to ensure accuracy and reliability.

Up to Date

Last updated: 2026-06-26

Important: This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.

Ready to take the next step?

Connect with top hospitals and specialists. Get personalized guidance for your medical journey.

Get Started Explore Treatments